Aura Biosciences (AURA) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Solid Biosciences (SLDB) has outperformed Aura Biosciences (AURA) over the past year, gaining 24.1% versus a gain of 12.2%. Solid Biosciences is the larger company by market cap ($717.9 million vs $664.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | SLDB |
|---|---|---|
| Share price | $6.41 | $6.70 |
| Market cap | $664.23M | $717.87M |
| 1-day change | -0.85% | -2.26% |
| YTD return | +18.53% | +21.45% |
| 1-year return | +12.15% | +24.09% |
| 5-year return | — | -79.70% |
| EPS (TTM) | $-1.75 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $11.45 |
| 52-week low | $4.73 | $3.79 |
| Distance from 52-week high | -32.83% | -41.53% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +159.17% | +178.12% |
| Average volume | 740.43K | 1.09M |
| Shares outstanding | 103.70M | 107.23M |
| Employees | 113 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed AURA by 11.9 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
AURA vs SLDB FAQ
Which is bigger, Aura Biosciences or Solid Biosciences?
Solid Biosciences (SLDB) is larger, with a market capitalization of $717.87M compared with $664.23M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or SLDB?
SLDB returned +24.09% over the past 12 months, compared with +12.15% for AURA (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.